Synthetic biology specialist Synlogic will start phase 3 testing of a drug for rare metabolic disorder phenylketonuria ... At the moment the main treatment strategy is to restrict phe in the ...

The firm, which plans to use the ticker symbol "MAZE" on the Nasdaq, develops drugs designed to mimic the protective effects ...